Palvella Therapeutics' QTORIN Rapamycin Phase 3 SELVA Trial Achieves Primary Endpoint, Shares Rally
Palvella Therapeutics saw its shares jump after its Phase 3 SELVA trial of QTORIN rapamycin met the primary efficacy endpoint in its interim analysis, demonstrating statistically significant results. The company now plans to pursue regulatory filings based on these positive outcomes.
1. Phase 3 SELVA Trial Success
Palvella’s SELVA trial, a randomized Phase 3 study of QTORIN rapamycin, delivered a positive interim readout by meeting its prespecified primary efficacy endpoint. The result demonstrates a statistically significant improvement in the trial’s key measure, validating the drug’s mechanism of action in the target patient population.
2. Share Reaction
Following the trial announcement, Palvella’s stock surged sharply on heavy volume as investors digested the milestone, reflecting heightened optimism over the drug’s commercial potential. The move added significant market capitalization ahead of further corporate updates.
3. Regulatory Next Steps
With the primary endpoint achieved, Palvella plans to engage with regulators to discuss the full data package and initiate preparations for a Biologics License Application. The company aims to leverage the positive outcome to accelerate its path toward potential approval.